1. Home
  2. BOWN vs CVKD Comparison

BOWN vs CVKD Comparison

Compare BOWN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOWN
  • CVKD
  • Stock Information
  • Founded
  • BOWN 2023
  • CVKD 2022
  • Country
  • BOWN United States
  • CVKD United States
  • Employees
  • BOWN N/A
  • CVKD N/A
  • Industry
  • BOWN
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • BOWN
  • CVKD Health Care
  • Exchange
  • BOWN Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • BOWN 28.5M
  • CVKD 29.5M
  • IPO Year
  • BOWN 2023
  • CVKD 2023
  • Fundamental
  • Price
  • BOWN $10.16
  • CVKD $12.90
  • Analyst Decision
  • BOWN
  • CVKD Strong Buy
  • Analyst Count
  • BOWN 0
  • CVKD 1
  • Target Price
  • BOWN N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • BOWN 2.8K
  • CVKD 34.8K
  • Earning Date
  • BOWN 01-01-0001
  • CVKD 08-06-2025
  • Dividend Yield
  • BOWN N/A
  • CVKD N/A
  • EPS Growth
  • BOWN N/A
  • CVKD N/A
  • EPS
  • BOWN 0.02
  • CVKD N/A
  • Revenue
  • BOWN N/A
  • CVKD N/A
  • Revenue This Year
  • BOWN N/A
  • CVKD N/A
  • Revenue Next Year
  • BOWN N/A
  • CVKD N/A
  • P/E Ratio
  • BOWN $222.49
  • CVKD N/A
  • Revenue Growth
  • BOWN N/A
  • CVKD N/A
  • 52 Week Low
  • BOWN $2.71
  • CVKD $5.70
  • 52 Week High
  • BOWN $19.77
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • BOWN 49.68
  • CVKD 49.22
  • Support Level
  • BOWN $8.70
  • CVKD $11.00
  • Resistance Level
  • BOWN $10.20
  • CVKD $13.56
  • Average True Range (ATR)
  • BOWN 0.43
  • CVKD 1.13
  • MACD
  • BOWN -0.03
  • CVKD 0.23
  • Stochastic Oscillator
  • BOWN 70.98
  • CVKD 78.32

About BOWN Bowen Acquisition Corp

Bowen Acquisition Corp is a blank check company.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: